Urology News and Research

Latest Urology News and Research

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.

29 Sep 2010

microRNA may provide quick diagnosis of bladder cancer

Scientists may have discovered a way to diagnose bladder cancer at its earliest and, therefore, most treatable stages by measuring the presence or absence of microRNA using already available laboratory tests.

29 Sep 2010

New predictive test to identify aggressive prostate cancer

S. Mark Redwood, M.D., chief of the Department of Urology at Sinai Hospital, is using a state-of-the-art predictive prostate cancer test called Prostate Px+ to better understand the aggressiveness of each individual patient's cancer and how best to treat it.

29 Sep 2010

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Afflicting countless people worldwide, chronic pain is a largely misunderstood and under-treated disease that forever alters the lives of more than 50 million Americans each year.

28 Sep 2010

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Apax Partners today announced that Endo Pharmaceuticals has entered into a definitive agreement to acquire Qualitest Pharmaceuticals for approximately $1.2 billion in cash. Qualitest, a portfolio company of Apax Partners since 2007, is the sixth largest generic pharmaceutical company in the U.S.

28 Sep 2010

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Endo Pharmaceuticals announced today that it has entered into a definitive agreement to acquire Qualitest Pharmaceuticals, a leading, privately held generics company in the U.S., for approximately $1.2 billion in cash.

28 Sep 2010

Clinical study results for patient-specific vaccine therapy to treat metastatic melanoma announced

Hoag Memorial Hospital Presbyterian recently announced encouraging clinical study results for patient-specific vaccine therapy to treat metastatic melanoma. The study is ongoing, but the report concludes that patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases, as demonstrated in one particular patient who participated in the trial.

28 Sep 2010

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Identification of a molecular communications pathway that influences the mobilization of hematopoietic (blood) stem cells could lead to targeted therapies for improving bone marrow transplant success rates.

27 Sep 2010

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.

27 Sep 2010

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.

24 Sep 2010

Warner Chilcott subsidiaries to issue $500 million of 7-3/4% senior notes in private placement

Warner Chilcott plc today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (together, the "Issuers"), plan to issue an aggregate principal amount of $500 million of 7-3/4% senior notes due 2018 (the "Notes") in a private placement. The notes are additional notes constituting a part of the same series as the $750 million aggregate principal amount of 7-3/4% senior notes due 2018 issued on August 20, 2010.

24 Sep 2010

Warner Chilcott to acquire U.S. rights to Enablex from Novartis for $400 million

Warner Chilcott plc today announced that it has agreed to terminate its existing co-promotion agreement with Novartis and signed a definitive agreement to purchase the U.S. rights to Enablex® from Novartis for $400 million in cash. Enablex (darifenacin) is a product indicated to treat adults with symptoms of overactive bladder, which had U.S. sales of approximately $190 million for the year ended December 31, 2009.

24 Sep 2010

Study: PTNS offers an effective treatment option for detrusor overactivity incontinence

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of a study "Percutaneous Tibial Nerve Stimulation Effects on Detrusor Overactivity Incontinence Are Not Due to a Placebo Effect A Randomized, Double-Blind, Placebo Controlled Trial," to be published in the November 2010 print edition of THE JOURNAL OF UROLOGY.

24 Sep 2010

Pet dog decreases risk of obesity in kids: Study

According to the latest research in England, children who have a dog for a pet are less likely to be obese. Children who are obese in childhood are at increased risk of developing a range of chronic health problems such as high blood pressure, high cholesterol levels, bone and joint problems, asthma, disrupted sleep patterns, liver and gall bladder disease, early physical maturity and depression.

23 Sep 2010

Vision-Sciences, Stryker sign urology supply agreement

Vision-Sciences, Inc. announced today that it has signed a three year agreement under which Vision-Sciences will become the exclusive supplier to Stryker Corporation, through its Endoscopy division, of Stryker-branded flexible video and fiber cystoscopes.

From Stryker 23 Sep 2010

Data shows preoperative Web-based interactive programs reduce hospital stays

Patients who participate in Web-based interactive programs prior to surgery have a significantly shorter length of stay than those who do not, according to new data. Preoperative education reinforces messages about care instructions and safety, and reduces the level of stress patients experience after their procedure - leading to improved efficiency and care.

23 Sep 2010

High selenium intake associated with lower rates of bladder cancer in women

Scientists in Spain have found that adding a can of tuna or other fish to our shopping lists could help protect us against bladder cancer.

23 Sep 2010

FDA grants priority review status for Endo’s oxymorphone oral formulation

Endo Pharmaceuticals announced that it recently received notification from the U.S. Food and Drug Administration (FDA) that Endo's new drug application (NDA) for its new oral formulation of long-acting oxymorphone, which is designed to be crush resistant, has been granted priority review status.

23 Sep 2010

AACR to host fourth International Conference on Molecular Diagnostics

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

22 Sep 2010

Prostate cancer - TRAIL is worth a trial

One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours at the Medical University of Vienna and Harvard Medical School, USA, have just been published. They show that the TRAIL protein opens up the prospect to a more accurate prediction of the disease's course, as well as the opportunity to identify a new intervention point for innovative therapies in advanced prostate cancer.

21 Sep 2010

Urology News and Research

Latest Urology News and Research

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

microRNA may provide quick diagnosis of bladder cancer

New predictive test to identify aggressive prostate cancer

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Clinical study results for patient-specific vaccine therapy to treat metastatic melanoma announced

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Warner Chilcott subsidiaries to issue $500 million of 7-3/4% senior notes in private placement

Warner Chilcott to acquire U.S. rights to Enablex from Novartis for $400 million

Study: PTNS offers an effective treatment option for detrusor overactivity incontinence

Pet dog decreases risk of obesity in kids: Study

Vision-Sciences, Stryker sign urology supply agreement

Data shows preoperative Web-based interactive programs reduce hospital stays

High selenium intake associated with lower rates of bladder cancer in women

FDA grants priority review status for Endo’s oxymorphone oral formulation

AACR to host fourth International Conference on Molecular Diagnostics

Prostate cancer - TRAIL is worth a trial

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Urology News and Research

Latest Urology News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in